Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves
An evidence-based triage plan for cellular therapy distribution is critical in the face of emerging constraints on healthcare resources. We evaluated the impact of treatment delays related to COVID-19 on patients scheduled to undergo hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy at our center.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Mariam T Nawas, Gunjan L. Shah, Darren R. Feldman, Josel D. Ruiz, Elizabeth V. Robilotti, Anoshe A. Aslam, Mary Dundas, Mini Kamboj, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio A. Giralt, Boglarka Gyurkocza, Oscar B. Lahoud, Source Type: research